Oruka Therapeutics Inc.
ORKA | NASDAQ
$95.53
-$1.34 (-1.38%)
Nov 2, 2026, 11:42 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 | FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 83K | 27K | 111K | 114K | 91K | 93K |
Gross Profit | -83K | -27K | -111K | -114K | -91K | -93K |
Operating Income | -122.05M | -88.12M | -7.3M | -9.84M | -19.34M | -9.77M |
Interest Income | 16.63M | 5.86M | 1.96M | 675K | n/a | n/a |
Pretax Income | -105.43M | -83.72M | -5.34M | -9.93M | -19.32M | -9.75M |
Net Income | -105.43M | -83.72M | -5.34M | -9.93M | -19.32M | -9.74M |
Selling & General & Admin | 21.33M | 13.04M | 6.17M | 5.26M | 5.41M | 4.68M |
Research & Development | 100.64M | 75.06M | 1.01M | 4.46M | 13.83M | 4.99M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 121.97M | 88.1M | 7.19M | 9.73M | 19.24M | 9.67M |
Interest Expense | n/a | 1.47M | n/a | n/a | n/a | 9K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 122.05M | 88.12M | 7.3M | 9.84M | 19.34M | 9.77M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | -9K |
Shares Outstanding (Basic) | 45.61M | 16.79M | 14.42M | 14.41M | 13.9M | 4.71M |
Shares Outstanding (Diluted) | 45.61M | 16.79M | 14.42M | 14.41M | 13.9M | 4.71M |
EPS (Basic) | -2.31 | -4.99 | -4.44 | -8.27 | -16.68 | -8.40 |
EPS (Diluted) | -2.31 | -4.99 | -4.44 | -8.27 | -16.68 | -8.40 |
EBITDA | -105.35M | -82.23M | -5.23M | -9.81M | -19.23M | -9.65M |
EBIT | -105.43M | -82.26M | -5.34M | -9.93M | -19.32M | -9.74M |
Depreciation & Amortization | 83K | 27K | 111K | 114K | 91K | 93K |
Add to Watchlist
Select watchlists to add or remove ORKA